Opendata, web and dolomites


Integration of high resolution -OMICS datasets towards personalized therapy in bladder cancer

Total Cost €


EC-Contrib. €






Project "TheranOMICS" data sheet

The following table provides information about the project.


Organization address
postcode: 30659

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 116˙250 €
 EC max contribution 116˙250 € (100%)
 Programme 1. H2020-EU. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-02-2016
 Funding Scheme /CSA
 Starting year 2017
 Duration (year-month-day) from 2017-09-29   to  2018-09-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOSAIQUES DIAGNOSTICS GMBH DE (HANNOVER) coordinator 116˙250.00


 Project objective

'TheranOMICS Project aims at the recruitment of a highly-qualified research Associate to support the Innovation Business Idea of Mosaiques diagnostics GmbH (MOS). The Associate is expected to have expertise in statistics, computer science and biology. The objective is the integration of high resolution bladder cancer (BC) –omics datasets that are available at MOS to establish molecular profiles which can predict disease outcome and treatment response. The tasks include application of state-of-the-art bioinformatics tools in the development of two predictive tools that together will be offered as a companion test to assist patient stratification and predict response in BC drug development. The first tool will be based on molecular features associated with the clinical status and will enable the stratification of BC patients to those with the higher probability to progress. The second tool will be built on molecules/biomarkers associated with drug response and will enable to prediction of success of chemotherapy, as a test case study. MOS Business Innovation Idea is the development of the above predictive tools, to be served as a 'business-to-business' product for pharmaceutical companies developing Bladder Cancer (BC) drugs. The expected outcome is the improved stratification of BC patients and the increased efficacy of new therapeutic agents. The benefit for the customers (Pharmaceutical Industry) is the reduction of the number of investigated subjects, time requirement and cost of clinical trials. The benefit for MOS enterprise is the opening of new marketing possibilities and the positioning in the Market of Pharmaceutical Industry. As a secondary aim, we target implementation of the tools for BC Patient management, aiming at improved, personalized intervention to prolong patients’ lives and increase their quality of life. Thus, TheranOMICS aims beyond the one-year period of INNOSUP support and provides perspectives for the Associate for a long-term employment.'

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERANOMICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERANOMICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.

CODIS (2018)

Co-create Design Innovation Services

Read More  

P2P Digital (2018)

P2P Digitalisation Support to SME

Read More  

SocEn (2018)

Peer Learning on Social Entrepreneurship and Social Enterprise Support

Read More